ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Anti-inflammatory and antinociceptive effects of a novel 1,5-benzodiazepine derivative in murine models.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the anti-inflammatory and analgesic potential of a novel 1,5-benzodiazepine derivative (MAL) using in vivo models and in silico molecular docking analysis. A total of 264 adult male Swiss albino mice were used for standard pharmacological investigations. MAL was administered at doses of 5, 10, 25, and 50 mg/kg. Diazepam (DZP), diclofenac, and acetaminophen (APAP) were used as reference drugs. Anti-inflammatory activity was assessed using carrageenan-induced paw edema, the air pouch model, and Evans blue-induced vascular permeability. Histopathological analysis was performed to evaluate tissue edema, leukocyte, and neutrophil infiltration. Analgesic effects were evaluated using tail-flick, hot plate, and acetic acid-induced writhing assays. Molecular docking studies were conducted to predict binding interactions of MAL with the α1A-adrenergic receptor (8THL) and COX-2 (3LN1), with results expressed as mean ± SEM. MAL significantly reduced paw edema, with maximal inhibition at 25 mg/kg (43.41% ± 4.23), compared with diclofenac (37.93% ± 3.67). Peak inhibition at 4 h reached 78.54% ± 0.43 for MAL, while 70.14% ± 0.22 for diclofenac. MAL markedly decreased leukocyte and neutrophil infiltration, vascular permeability (66.39% ± 4.18 vs 53.40% ± 4.40), and neutrophil migration in the air pouch, confirmed by histology. Analgesic activity was significant and comparable to standard drugs, supporting both central and peripheral mechanisms. Docking analysis revealed strong binding affinities (- 8.9 and - 8.5 kcal/mol), exceeding reference drugs. MAL exhibits potent anti-inflammatory and analgesic properties, particularly at 25 mg/kg, reducing neutrophil-mediated inflammation, and represents a promising candidate for further pharmacological development.
Indexed as
Identifiers
42429829What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.